Imaging Dementia Evidence for Amyloid Scanning (IDEAS) (CLOSED)
What is the IDEAS Study?
The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will determine the clinical usefulness on patient-oriented outcomes of a brain positron emission tomography (PET) scan that detects amyloid plaques, a core feature of Alzheimer’s disease. In addition to assessing the impact of amyloid PET on management of patients with mild cognitive impairment or dementia of uncertain cause, the study will compare medical outcomes for study participants with matched patients not in the study.
What is the Purpose of IDEAS?
By providing access to amyloid imaging for more than 18,000 Medicare beneficiaries for whom there is ambiguity about the cause of their cognitive decline/dementia, the IDEAS Study seeks to demonstrate that amyloid PET can help clinicians diagnose the cause of cognitive impairment, provide the most appropriate treatments and recommendations, and improve health outcomes. It is anticipated that the evidence obtained by the IDEAS Study will support reimbursement of amyloid imaging by Medicare and other third-party payers.
Medicare beneficiaries, age 65 or older, who have a progressive, unexplained mild cognitive impairment, or have dementia symptoms of uncertain cause due to atypical or mixed symptoms, or have an unusually early age-of-onset. A dementia specialist must make the referral to the study.
Please review the IDEAS Study Brochure for additional details about the trial.
If you are interested in learning more about the IDEAS study, please call (401) 455-6403 or send an e-mail to: email@example.com. Ask about the “IDEAS study.”